At the time of writing, uniQure N.V [QURE] stock is trading at $15.2, up 5.41%. An important factor to consider is whether the stock is rising or falling in short-term value. The QURE shares have gain 2.15% over the last week, with a monthly amount glided 0.60%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Raymond James upgraded its rating to Strong Buy on December 10, 2024. Goldman downgraded its rating to a Neutral but stick to its price target of $8 on February 29, 2024. Mizuho downgraded its rating to a Neutral and reduced its price target to $10 on December 19, 2023. UBS upgraded its rating to Buy for this stock on March 17, 2022, but kept the price target unchanged to $40. In a note dated June 15, 2021, BTIG Research initiated an Buy rating and provided a target price of $46 on this stock.
For the past year, the stock price of uniQure N.V fluctuated between $4.45 and $19.18. Currently, Wall Street analysts expect the stock to reach $30 within the next 12 months. uniQure N.V [NASDAQ: QURE] shares were valued at $15.2 at the most recent close of the market. An investor can expect a potential return of 97.37% based on the average QURE price forecast.
Analyzing the QURE fundamentals
According to uniQure N.V [NASDAQ:QURE], the company’s sales were 20.20M for trailing twelve months, which represents an -81.53% plunge. Gross Profit Margin for this corporation currently stands at 0.41% with Operating Profit Margin at -8.55%, Pretax Profit Margin comes in at -10.66%, and Net Profit Margin reading is -10.77%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -4.84 and Total Capital is -0.3. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.97.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that uniQure N.V [NASDAQ:QURE] has a current ratio of 11.99. On the other hand, the Quick Ratio is 11.99, and the Cash Ratio is 5.98. Considering the valuation of this stock, the price to sales ratio is 41.20, the price to book ratio is 24.68.
Transactions by insiders
Recent insider trading involved Abi-Saab Walid, Chief Medical Officer, that happened on Jun 27 ’25 when 1466.0 shares were sold. Director, Springhorn Jeremy P. completed a deal on Jun 20 ’25 to sell 2112.0 shares. Meanwhile, Director POST LEONARD E sold 2112.0 shares on Jun 20 ’25.
